24/7 Market News Snapshot 22 September, 2025 – MBX Biosciences, Inc. Common Stock (NASDAQ:MBX)
DENVER, Colo., 22 September, 2025 (www.247marketnews.com) – (NASDAQ:MBX) are discussed in this article.
MBX Biosciences, Inc. (MBX) is experiencing significant market enthusiasm, with its stock price surging to $14.95, reflecting a remarkable 49.47% increase from the previous close of $10.00 in a pre-market session marked by high trading volume of 2.04 million shares. This bullish trend signals a growing investor confidence, driven by the recent announcement of encouraging results from the Phase 2 Avail™ trial for canvuparatide, a pioneering once-weekly treatment for chronic hypoparathyroidism (HP).
The Avail™ trial met its primary endpoint, evidencing that 63% of participants achieved positive outcomes at the 12-week mark. The results demonstrated statistically significant maintenance of serum calcium levels while reducing reliance on existing therapies. Engaging 64 adult participants, the trial successfully retained 94% who chose to continue into the open-label extension phase, with a remarkable 79% maintaining their responder status at six months.
Dr. Mishaela Rubin, a lead investigator, underscored the potential of canvuparatide to simplify management for HP patients, who typically navigate the complexities of established treatments. Notably, the trial reported a favorable safety profile, free of serious treatment-related adverse events, further positioning canvuparatide as an effective candidate for HP management.
Kent Hawryluk, President and CEO of MBX Biosciences, conveyed excitement about these findings, asserting that canvuparatide could markedly improve the standard of care for HP patients. With plans to launch a Phase 3 trial in 2026, MBX is committed to progressing this innovative therapy.
Patty Keating, Executive Director of the HypoPARAthyroidism Association, praised the trial’s implications, emphasizing that a once-weekly option would greatly alleviate the daily burdens for those in the HP community. Stakeholders are keenly awaiting further data presentations at upcoming medical meetings as MBX moves forward in the development of canvuparatide.
Related news for (MBX)
- MBX Biosciences Announces Once-Weekly Canvuparatide Achieved Primary Endpoint in Phase 2 Trial with 63% Responder Rate at 12 Weeks; 79% Responder Rate at 6 Months in Open-Label Extension
- MoBot’s Stock Market Highlights – 09/22/25 07:00 AM
- Breaking News: MoBot’s Latest Update as of 09/19/25 05:00 PM
- MBX Biosciences Announces IND Submission of MBX 4291, its Long-acting GLP1/GIP Receptor Co-agonist Prodrug for the Treatment of Obesity